Benign prostatic hyperplasia is an age-associated prostate gland enlargement and is a common condition in men as they get older. As per DelveInsight’s Benign Prostatic Hyperplasia Devices Market analysis, the total eligible patient population for BPH in 7MM is expected to increase at a CAGR of 2.58% during the study period 2018-2026.
The key companies in the Benign Prostatic Hyperplasia market include Olympus Medical Americas, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Inc., Zenflow, Inc., ProArc Medical, and Medion Biodesign.
The treatment algorithm for Benign Prostatic Hyperplasia (BPH) includes pharmacotherapy, traditional surgeries, and medical device implantation. The medical devices hold future promise as it a minimum invasive procedure and also require hospitalization of less than a day and the patient can return to normal life immediately. The BPH devices market is estimated to increase due to advancements in healthcare technology, high healthcare expenditure, and available reimbursement policies in developed countries. The approval of new devices and the growing geriatric population globally will also stimulate market growth.
For more details, visit: Benign Prostatic Hyperplasia (BPH) Devices Market